CRP and myocardial infarction: The canakinumab anti‐inflammatory thrombosis outcomes (CANTOS) study has shown that antagonism of IL‐1β reduces recurrent myocardial infarction in patients with plasma C‐reactive protein (CRP) levels >2 mg/L, suggesting an important role for IL‐1β induced inflammation in CVD.9